ADMA BIOLOGICS, INC.
ADMANasdaq
$8.71
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -50.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$2.1B
P/E
12.8
P/S
4.1
P/B
5.4
EV/EBITDA
9.6
PEG
—
FCF Yield
5.2%
Dividend Yield
—
Revenue (TTM)
$509.9M
Net Income (TTM)
$165.4M
Free Cash Flow (TTM)
$107.9M
Gross Margin
61.3%
Operating Margin
42.1%
Net Margin
32.4%
ROE
42.4%
ROIC
38.3%
Debt / Equity
0.5
Net Cash
-$58.7M
Return 1Y
-50.5%
Company profile
ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.
- CEO
- Adam S. Grossman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 530
- Headquarters
- New Jersey
- Website
- admabiologics.com
Management & directors
- Kohler TerryCFO and Treasurer
- Kestenberg-Messina Kaitlin M.COO and SVP, Compliance
- Grossman Adam SPresident and CEO
- Tade Brad L.CFO and Treasurer
Roles derived from SEC Form 4 filings.
Earnings
ADMA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$114.5M↓ -0.3%
Diluted EPS$0.19↑ +72.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Gross profit | -$19.1M | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| Operating income | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| Net income | -$75.7M | -$71.7M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| Diluted EPS | -$0.88 | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
| Operating cash flow | -$102.0M | -$112.4M | -$59.5M | $8.8M | $118.7M | $50.4M |
| Free cash flow | -$114.7M | -$125.9M | -$73.4M | $4.0M | $110.4M | $27.8M |
| Gross margin | -45.2% | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Operating margin | -153.8% | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
| Net margin | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $107.2M | $119.8M | $117.5M | $114.8M | $122.0M | $134.2M | $139.2M | $114.5M |
| Gross profit | $57.5M | $59.7M | $63.3M | $61.1M | $67.2M | $75.6M | $88.8M | $80.8M |
| Operating income | $39.2M | $39.6M | $38.3M | $34.9M | $42.8M | $51.0M | $62.8M | $58.3M |
| Net income | $32.1M | $35.9M | $111.9M | $26.9M | $34.2M | $36.4M | $49.4M | $45.3M |
| Diluted EPS | $0.13 | $0.15 | $0.45 | $0.11 | $0.14 | $0.15 | $0.20 | $0.19 |
| Operating cash flow | $45.6M | $25.0M | $50.2M | -$19.7M | $21.1M | $13.3M | $35.6M | $58.2M |
| Free cash flow | $43.6M | $24.0M | $47.5M | -$24.4M | $18.7M | -$1.1M | $34.6M | $55.7M |
| Gross margin | 53.6% | 49.8% | 53.9% | 53.2% | 55.1% | 56.3% | 63.8% | 70.5% |
| Operating margin | 36.6% | 33.1% | 32.6% | 30.4% | 35.1% | 38.0% | 45.1% | 50.9% |
| Net margin | 29.9% | 30.0% | 95.2% | 23.4% | 28.1% | 27.1% | 35.5% | 39.6% |
Company news
Jul 15, 2026
Jul 13, 2026
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Kohler Terry· CFO and Treasurer | Award | 85,130 | $0.00 | $0.00 | filing |
| 2026-05-27 | Grossman Jerrold B | Buy | 6,400 | $7.91 | $50,624.00 | filing |
| 2026-05-12 | Grossman Jerrold B | Buy | 12,500 | $8.01 | $100,125.00 | filing |
| 2026-05-11 | Grossman Jerrold B | Buy | 12,500 | $8.01 | $100,125.00 | filing |
| 2026-04-01 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Tax withholding | 20,362 | $9.11 | $185,497.82 | filing |
| 2026-03-17 | Guiheen Lawrence P. | Gift | 30,000 | $0.00 | $0.00 | filing |
| 2026-03-17 | Guiheen Lawrence P. | Gift | 30,000 | $0.00 | $0.00 | filing |
| 2026-03-16 | Grossman Adam S· President and CEO | Sale | 15,000 | $15.16 | $227,400.00 | filing |
| 2026-03-16 | Grossman Adam S· President and CEO | Sale | 6,000 | $15.16 | $90,960.00 | filing |
| 2026-03-16 | Grossman Adam S· President and CEO | Option exercise | 15,000 | $5.40 | $81,000.00 | filing |
| 2026-03-13 | Guiheen Lawrence P. | Option exercise | 30,000 | $3.66 | $109,800.00 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Sale | 10,096 | $15.63 | $157,800.48 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Option exercise | 2,500 | $5.00 | $12,500.00 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Option exercise | 2,646 | $2.83 | $7,488.18 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Option exercise | 1,250 | $4.31 | $5,387.50 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Option exercise | 1,525 | $2.35 | $3,583.75 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Option exercise | 2,175 | $1.55 | $3,371.25 | filing |
| 2026-03-09 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | J | 91,266 | $0.00 | $0.00 | filing |
| 2026-03-07 | Grossman Adam S· President and CEO | Tax withholding | 29,513 | $15.39 | $454,205.07 | filing |
| 2026-03-07 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Tax withholding | 4,235 | $15.39 | $65,176.65 | filing |
| 2026-03-06 | Grossman Adam S· President and CEO | Tax withholding | 56,438 | $15.39 | $868,580.82 | filing |
| 2026-03-06 | Kestenberg-Messina Kaitlin M.· COO and SVP, Compliance | Tax withholding | 10,059 | $15.39 | $154,808.01 | filing |
| 2026-03-06 | ELMS STEVE | Buy | 7,000 | $15.39 | $107,730.00 | filing |
| 2026-03-05 | ELMS STEVE | Buy | 7,000 | $15.67 | $109,690.00 | filing |
| 2026-02-26 | Grossman Adam S· President and CEO | Tax withholding | 54,858 | $15.18 | $832,744.44 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.